OncoMatch/Leukemia — Acute Myeloid (AML)/IDH1
Leukemia — Acute Myeloid (AML)IDH1 Clinical Trials
IDH1 mutations occur in 7–10% of AML and produce the oncometabolite 2-hydroxyglutarate (2-HG), driving epigenetic dysregulation and differentiation block. Ivosidenib is FDA-approved as monotherapy for relapsed/refractory IDH1-mutant AML and in combination with azacitidine for newly diagnosed patients ineligible for intensive chemotherapy. Trials investigate ivosidenib combinations with venetoclax, HMA/venetoclax triplets, and 2-HG as a pharmacodynamic biomarker.
Top recruiting IDH1 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier Affaires Médicales
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Alice Mims
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital